2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
7
Prostatic Neoplasms
5
Brain Neoplasms
5
Carcinoma, Non-Small-Cell Lung
3
Radiation Injuries
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hemangioma
2
Breast Neoplasms
2
Urogenital Neoplasms
1
Scleroderma, Localized
1
Respiratory Distress Syndrome
1
Radiation Pneumonitis
1
Popliteal Cyst
1
Polycystic Ovary Syndrome
1
Pneumonia, Viral
1
Pneumonia
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Optic Neuritis
1
Neurodermatitis
1
Neoplastic Cells, Circulating
1
Neoplasms, Fibrous Tissue
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms by Histologic Type
1
Neoplasm, Residual
1
Nasopharyngeal Carcinoma
1
Interventions
Mycophenolic Acid
2
Blood Specimen Collection
2
vedolizumab
1
bavituximab
1
Ursodeoxycholic Acid
1
Surveys and Questionnaires
1
Steroids
1
Spermine Synthase
1
Sorafenib
1
Sofosbuvir
1
Ribavirin
1
Prednisone
1
Photopheresis
1
Phlebotomy
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Methoxsalen
1
Liquid Biopsy
1
Infliximab
1
Clinical Protocols
1
Azathioprine
1
Adrenal Cortex Hormones
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hepatitis
×
Adrenal Cortex Hormones
×
Clear all
NCT04810156
2022-12-14
I-HEP
Herlev Hospital
Phase 2
Unknown
60 enrolled